- Home
- ATYR vs CMBM Comparison
ATYR vs CMBM Comparison
Compare ATYR & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | CMBM |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 65.5M |
| IPO Year | 2015 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ATYR | CMBM |
|---|---|---|
| Price | $0.71 | $1.75 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.75 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 445.5K |
| Earning Date | 11-06-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $190,000.00 | ★ $172,215,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | $18.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $0.23 |
| 52 Week High | $7.29 | $6.80 |
Technical Indicators
Market Signals| Indicator | ATYR | CMBM |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 54.44 |
| Support Level | $0.66 | $1.44 |
| Resistance Level | $0.74 | $1.68 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 29.11 | 87.48 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.